United States (USA) Immunoassays Market Overview, 2031

Key Insights

• Driven by clinical efficiency demands, the US immunoassay market is projected to expand, capturing a significant portion of overall diagnostic testing. Concurrently, demographic shifts are heavily accelerating this volume, the US senior population (aged 65 and older) expanded to 61.2 million, heavily scaling the volume of decentralized immunoassay testing needed for routine chronic disease tracking and therapeutic drug monitoring.
• Traditional chemiluminescence immunoassays (CLIA) require time-consuming washing and fluidic separation steps. A massive technological leap forward is the development of homogeneous chemiluminescence. Companies are introducing one-step assays that eliminate wash cycles completely, dropping testing turnaround times down to under 3 minutes and vastly shrinking analyzer hardware footprints.
• A major breakthrough in the US market is the transition of immunoassays from traditional infectious disease testing into ultra-precise neurology diagnostics. Innovations like digital immunoassays (detecting proteins at femtomolar levels) have enabled high-accuracy blood tests. For instance, Quanterix's Lucent Diagnostics expanded its line with a high-accuracy p-Tau 217 blood immunoassay for early Alzheimer’s screening, offering a scalable method to detect amyloid pathology before severe symptoms occur.

Market Outlook

• According to the research report, "United States Immunoassays Market Outlook, 2031," published by Bonafide Research, the United States Immunoassays Market was valued at more than 10.80 Billion in 2025.
• US clinical environments points to complete workflow standardization. Heavy infrastructure shifts are favoring fully automated high-throughput analyzer platforms (such as Revvity's automated IDS i20 platform) paired with rapid, non-invasive specimen testing shifting standard assay volume from invasive draws to saliva and urine. The ecosystem is strictly regulated and standardized under organizations like the American Association for Clinical Chemistry (AACC) and the Clinical and Laboratory Standards Institute (CLSI). The competitive landscape is heavily consolidated around major industry giants including Abbott Laboratories, Roche Diagnostics, Beckman Coulter (Danaher), Siemens Healthineers, and Revvity.
• The market is steadily moving toward smart testing kits integrated with AI-driven data management platforms to flag abnormal biomarker variations automatically. Furthermore, the development of stable, dry-chemistry immunoassay kits is actively removing traditional cold-chain refrigeration requirements, allowing advanced diagnostic testing to move effortlessly into remote or underfunded US community clinics.

Market Dynamics

Driver: Prevalence of chronic and infectious diseases
The primary catalyst for the US immunoassay market is the expanding patient pool requiring ongoing diagnostic monitoring. Long-term conditions such as diabetes, cardiovascular disorders, cancer, and autoimmune diseases necessitate continuous biomarker evaluation to adjust therapeutic regimens. Additionally, seasonal surges of respiratory infections (such as influenza and RSV) require prompt, definitive identification in urgent care and emergency settings, consistently fueling the demand for high-volume immunoassay kits.
Challenge: High capital costs of advanced automated systems
While modern laboratories heavily favor automated and multiplex immunoassay platforms to mitigate staff shortages, the substantial upfront acquisition cost remains a barrier. Small-to-mid-sized clinical laboratories and community hospitals face strict budgetary constraints when investing in high-end chemiluminescence (CLIA) systems. Beyond initial instrument costs, ongoing reagent dependencies, specialized maintenance agreements, and required operator training keep overhead exceptionally high.
Trend: Growth of multiplex and microarray panels
A major directional shift in the US market is the transition from single-analyte testing (like classic ELISA) toward multiplexing. Clinicians increasingly favor panels that can simultaneously screen for multiple separate biomarkers from a single, minute patient sample. This trend is highly pronounced in oncology diagnostic testing and autoimmune profiling, where cross-examining multiple cytokine or antibody tracks at once shortens the diagnostic timeline and drastically reduces sample-handling labor.

Policies

• FDA Premarket Review (510(k), De Novo, or PMA): Immunoassay test kits and analyzer hardware are regulated as In Vitro Diagnostic (IVD) medical devices. Most standard immunoassay systems require an FDA 510(k) clearance to prove they are substantially equivalent to an existing legal device. Novel, high-risk, or unique companion diagnostic assays require a more stringent Premarket Approval (PMA) or a De Novo classification path.
• CLIA Complexity Categorization: Administered by the FDA’s Center for Devices and Radiological Health (CDRH), every cleared immunoassay is formally assigned a complexity score based on criteria like required technical knowledge, training, and operational stability.
• CMS Laboratory Certification: Under the Clinical Laboratory Improvement Amendments (CLIA), any US facility accepting human specimens for health assessments must hold a valid, active CLIA certificate matching the complexity tier of the immunoassay system they operate. To maintain certification, labs must submit all survey fees via the mandatory online federal portal.
• Mandatory Proficiency Testing (PT): To ensure accuracy and reliability across the industry, CLIA regulations force laboratories to participate in external, formalized proficiency testing programs. Laboratories are periodically sent blind control samples to analyze, and their results must fall strictly within the federally accepted performance limits for that specific analyte to maintain legal operation.

Segment Analysis

USA Immunoassays By Technology
• Chemiluminescence immunoassays dominate high-throughput clinical testing in the United States because they integrate seamlessly with automated laboratory analyzers used in hospital networks and independent laboratories. Their ability to deliver rapid turnaround times with minimal manual intervention has made them the preferred technology for routine testing in endocrinology, infectious diseases, and cardiac biomarkers.
• ELISA remains an essential technology across diagnostic laboratories, academic research institutions, and public health organizations. In the U.S., it continues to serve as a versatile platform for confirmatory testing, epidemiological studies, and biomarker discovery due to its adaptability to diverse analytes.
• Fluorescence-based immunoassays are increasingly utilized where rapid detection and enhanced analytical sensitivity are required. Point-of-care systems incorporating fluorescence detection are expanding their presence in emergency departments, outpatient clinics, and decentralized healthcare settings across the U.S. Indirect fluorescence assays also retain an important role in autoimmune diagnostics, where microscopic interpretation provides valuable clinical insight.
• Although radioimmunoassay has become less common in routine clinical diagnostics, they continue to be employed in specialized laboratories requiring highly sensitive hormone or research applications. Regulatory oversight related to radioactive materials and specialized disposal requirements has limited broader adoption, yet the technology remains valuable for certain niche assays where established clinical validation continues to support its use.
• ELISpot technology is gaining importance within immunology research, vaccine development, and cellular immune response monitoring. U.S. pharmaceutical companies and academic medical centers increasingly use ELISpot to evaluate T-cell functionality during clinical trials and immunotherapy development. Its capability to measure immune responses at the single-cell level makes it particularly valuable in translational medicine.
• Western blot continues to serve primarily as a confirmatory analytical method rather than a frontline diagnostic tool. In the U.S., its utilization has shifted toward specialized laboratories, research facilities, and applications requiring protein characterization.
• Multiplex immunoassays are transforming laboratory workflows by enabling simultaneous measurement of multiple biomarkers from a single patient sample. U.S. healthcare providers increasingly employ multiplex platforms in precision medicine, inflammatory disease assessment, oncology research, and companion diagnostics.

USA Immunoassays By Application
• Infectious disease testing represents one of the most established applications for immunoassays in the United States. Healthcare providers rely on immunoassays for screening, diagnosis, and surveillance of viral, bacterial, and parasitic infections across hospitals, reference laboratories, and blood donation centers.
• Immunoassays are fundamental to endocrine diagnostics because they provide efficient measurement of hormones involved in thyroid function, reproductive health, adrenal disorders, and metabolic regulation. U.S. clinical laboratories prioritize highly automated endocrine testing to manage chronic disease monitoring while maintaining consistent analytical performance across large patient populations.
• The oncology segment increasingly incorporates immunoassays for tumor marker measurement, treatment monitoring, and disease recurrence assessment. While molecular diagnostics have expanded cancer testing capabilities, immunoassays remain important complementary tools because of their accessibility, established clinical utility, and compatibility with routine laboratory workflows.
• Cardiac immunoassays are widely used in emergency medicine for rapid assessment of suspected cardiovascular events. Biomarker testing supports timely clinical decision-making by helping physicians evaluate myocardial injury, heart failure, and cardiovascular risk.
• Autoimmune disease diagnostics depend heavily on immunoassays capable of detecting disease-specific autoantibodies. U.S. healthcare providers increasingly utilize automated autoimmune testing platforms to improve laboratory efficiency while supporting earlier diagnosis of chronic immune-mediated disorders.
• Therapeutic drug monitoring utilizes immunoassays to optimize medication dosing and improve patient safety, particularly for drugs with narrow therapeutic windows. U.S. hospitals and clinical laboratories employ these assays to support individualized treatment strategies, reduce adverse drug events, and enhance long-term management of transplant recipients, epilepsy patients, and individuals receiving immunosuppressive therapies.
• Allergy immunoassays enable quantitative assessment of allergen-specific antibodies without requiring direct patient exposure to allergens. The U.S. market increasingly favors laboratory-based allergy testing because it complements clinical evaluation and supports personalized allergy management.

USA Immunoassays By Product
• Reagents and kits represent the operational foundation of immunoassay testing because they determine assay specificity, consistency, and clinical performance. U.S. laboratories frequently prioritize standardized reagent systems that integrate with automated analyzers while supporting regulatory compliance, quality assurance, and laboratory accreditation requirements.
• Modern immunoassay analyzers emphasize automation, workflow optimization, and interoperability with laboratory information systems. Healthcare providers in the United States increasingly adopt integrated analyzers capable of handling diverse testing volumes while minimizing manual handling and operational complexity. Manufacturers continue to differentiate their platforms through enhanced throughput flexibility, maintenance efficiency, and connectivity features.
• Software solutions are becoming increasingly important as laboratories pursue digital transformation and operational efficiency. Advanced software supports instrument management, quality control monitoring, data integration, and regulatory documentation, while service offerings focus on preventive maintenance, technical support, workflow optimization, and user training. These capabilities help laboratories maximize instrument uptime and maintain consistent diagnostic performance.

USA Immunoassays By End-User
• Hospitals and clinics represent major users of immunoassays because they require rapid diagnostic information for emergency care, inpatient management, and routine outpatient services. Integrated healthcare systems increasingly favor automated immunoassay platforms that support continuous operation, standardized workflows, and efficient clinical decision-making across multiple departments.
• Clinical laboratories perform a broad spectrum of immunoassay testing and serve as central diagnostic hubs within the U.S. healthcare system. Independent reference laboratories and regional laboratory networks increasingly invest in scalable automation, advanced quality management systems, and expanded testing portfolios to meet growing demand while maintaining operational efficiency and analytical consistency.
• Blood banks utilize immunoassays primarily to ensure the safety of donated blood through comprehensive infectious disease screening. High assay reliability, standardized testing protocols, and regulatory compliance remain essential priorities. Continuous improvements in screening technologies contribute to maintaining public confidence in the nation's blood supply.
• Pharmaceutical and biotechnology companies extensively employ immunoassays throughout drug discovery, preclinical research, clinical development, and biologics manufacturing. These organizations use immunoassays for biomarker validation, pharmacodynamic assessment, immunogenicity evaluation, and companion diagnostic development.
• Other end users include academic research institutions, government laboratories, public health agencies, forensic laboratories, and contract research organizations. These organizations use immunoassays for epidemiological studies, translational research, environmental monitoring, vaccine evaluation, and specialized analytical applications.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Immunoassays Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Technology
• Chemiluminescence Immunoassays (CLIA)
• Enzyme Immunoassays (ELISA/EIA)
• Fluorescence Immunoassays (FIA/IFA/ELFA)
• Radioimmunoassays (RIA)
• Rapid/Lateral Flow Immunoassays
• ELISpot
• Western Blot
• Multiplex & Other Immunoassays

By Application
• Infectious Disease Testing
• Endocrinology Testing
• Oncology Testing
• Cardiology Testing
• Autoimmune Disease Testing
• Therapeutic Drug Monitoring
• Allergy Diagnostics
• Other Applications

By Product
• Reagents & Kits
• Analyzers & Instruments
• Software & Services

By End User
• Hospitals & Clinics
• Clinical Laboratories
• Blood Banks
• Pharmaceutical & Biotechnology Companies
• Others